Don’t miss – Page 16 – Endpoints News

SUBSCRIBE

AACR roundup: Checkpoint cocktails score early successes as Roche's triple shows high response rate in frontline triple negative breast cancer

6 months ago

Novartis just signed a $1.6B buyout pact with a lead player in an emerging anti-inflammatory field

6 months ago

AstraZeneca CEO Soriot bets up to $7B on a major league collaboration for a game-changing HER2 cancer drug

6 months ago

Sure Hervé Hoppenot took a big cut in compensation after a pipeline disaster. But he still outscored the only woman on the list

6 months ago

After a 33-year odyssey, Jeffrey Bluestone grabs a ringside seat to watch his drug teplizumab go back into the clinic

6 months ago

Eli Lilly joins a troika of Big Pharmas that have tied up to a low-profile biotech with big aspirations in autoimmune disease, cancer

6 months ago

Blockbuster to be? Novartis snags a major win as FDA OKs a top PhIII drug -- will a pricing controversy follow?

6 months ago

Buyout vote looming, Celgene files for ozanimod OK (again), with a multibillion-dollar bet riding on every step

6 months ago

Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system

6 months ago

Price hikes, a strategic retreat and 1 big new approval has shaken up the rankings of the 20 most expensive drugs on the planet

6 months ago

Thermo Fisher forges $1.7 billion deal to buy a contract player in the booming gene therapy field

6 months ago

Allergan chief Brent Saunders bows to activists, but Appaloosa blasts back that it's all too little, too late

7 months ago

Hard-charging GSK research chief Hal Barron touts improved anti-BCMA data, aiming for fast applications

7 months ago

$757M and 5 years later, Celgene abandoned a biotech partner, triggering layoffs

7 months ago

Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

7 months ago

Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab

7 months ago

Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field

7 months ago

Oncology dominates a 'Cambrian explosion' in China's drug pipeline as McKinsey guru bets on a burst of innovation

7 months ago

Little Dermira’s shares zoom up on promising PhIIb atopic dermatitis data — but the road ahead is ultra risky and flanked by heavily armed giants

7 months ago

Gilead CEO Milligan capped a rocky year — and his career — with the new #1 compensation package in the big leagues of biopharma

7 months ago

The world's top 10 blockbusters — and what they tell us about R&D trends

7 months ago

Novartis' Sandoz chief is walking out in the middle of a global revamp, fueling fresh buzz about a spinoff

7 months ago

Emma Walmsley earns £1M pay rise in her first full year at GSK's helm — but £5.9M package still trails other Big Pharma CEOs

7 months ago

Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17

7 months ago

First page Previous page 13 14 151617 18 19 Next page Last page